Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100022/S045

Zilver PTX Drug-Eluting Peripheral Stent

Cook Ireland, Ltd. · Decision date Mar 25, 2026

FDA DECISIONP100022/S045

What did the FDA decide?

FDA records P100022/S045 as a supplement to PMA P100022, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 25, 2026.

FDA approval order statement

an approval for a change in the annual monitoring stability study sampling plan
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Mar 25, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P100022/S045
Regulatory pathway
PMA supplement
Product code
NIU
Decision code
OK30
Decision date
Mar 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, superficial femoral artery, drug-eluting.

Product code
NIU
FDA device class
3

For the original device and its historical approval scope, see PMA P100022. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P100022 · Original PMA

    ZILVER PTX DRUG-ELUTING PERIPHERAL STENT

  2. P100022/S045 received

    Application receipt date recorded by FDA.

  3. P100022/S045 · FDA decision

    30-Day Notice

  4. P100022/S046 · Related supplement

    Zilver PTX Drug-Eluting Peripheral Stent

Timeline entries are records held by MedtechLedger for P100022. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100022

Product / regulatory recordCompanyPathwayDecision dateSource
Cook Ireland, Ltd.PMA approvalNov 14, 2012FDA
Cook Ireland, Ltd.PMA supplementNov 6, 2026FDA

Explore the linked device profile

Other records with product code NIU

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA supplementAug 21, 2026FDA
Boston Scientific CorpPMA supplementAug 6, 2026FDA
Boston Scientific CorpPMA supplementJan 30, 2026FDA
Boston Scientific CorpPMA supplementOct 24, 2025FDA
Boston Scientific CorpPMA supplementAug 8, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cook Ireland, Ltd.

Headquarters
Not reported
Brand website
cookmedical.com
FDA applicant address
O' Halloran Rd., National Technology Park, Limerick

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records